Using PRRT with 177Lu-DOTATATE before surgery is both safe and effective for patients with non-functioning pancreatic neuroendocrine tumors and certain risk factors, according to the results of the NEOLUPANET trial. The Phase II study reported a 58% rate of partial tumor reduction, stable disease in the remaining patients, and no cases of tumor progression. Non-functioning … Continue reading Phase II Trial Shows Promise for Pre-Surgical PRRT in Pancreatic Neuroendocrine Tumors